Literature DB >> 25302847

Angiotensin II in inflammation, immunity and rheumatoid arthritis.

Y Chang1, W Wei.   

Abstract

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that is characterized by increased cardiovascular morbidity and mortality, independent of the traditional risk factors for cardiovascular disease. Although classically known for its role in the regulation of circulatory homeostasis, angiotensin II (Ang II) is recognized to act as a powerful proinflammatory mediator. Some research has showed that Ang II plays important roles in autoimmune diseases, including RA, systemic lupus erythematosus and multiple sclerosis. Ang II blockers prove effective in reducing inflammation and autoimmunity in rheumatic diseases and their relative safety, together with their effects for reducing the cardiovascular disease risk, suggest that Ang II blockers may at least act as effective adjunctive therapy for disease control in patients with RA. The present review focuses systematically on the potential impact of Ang II and its receptors on inflammation and immunomodulation in patients with RA.
© 2014 British Society for Immunology.

Entities:  

Keywords:  angiotensin II; immunity; inflammation; rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 25302847      PMCID: PMC4298392          DOI: 10.1111/cei.12467

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  99 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.

Authors:  Emma S Jones; M Jane Black; Robert E Widdop
Journal:  J Mol Cell Cardiol       Date:  2004-11       Impact factor: 5.000

3.  Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action.

Authors:  Paresh Dandona; Vikramjeet Kumar; Ahmad Aljada; Husam Ghanim; Tufail Syed; Debborah Hofmayer; Priya Mohanty; Devjit Tripathy; Rajesh Garg
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

4.  Angiotensin converting enzyme: induction by steroids in rabbit alveolar macrophages in culture.

Authors:  J Friedland; C Setton; E Silverstein
Journal:  Science       Date:  1977-07-01       Impact factor: 47.728

5.  Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury.

Authors:  Jing Shao; Masaomi Nangaku; Toshio Miyata; Reiko Inagi; Koei Yamada; Kiyoshi Kurokawa; Toshiro Fujita
Journal:  Hypertension       Date:  2003-05-27       Impact factor: 10.190

Review 6.  Mechanisms and treatment of allergic disease in the big picture of regulatory T cells.

Authors:  Cezmi A Akdis; Mübeccel Akdis
Journal:  J Allergy Clin Immunol       Date:  2009-04       Impact factor: 10.793

7.  Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice.

Authors:  Lucia Mazzolai; Michel A Duchosal; Martine Korber; Karima Bouzourene; Jean François Aubert; Hiroyuki Hao; Veronique Vallet; Hans-R Brunner; Jürg Nussberger; Giulio Gabbiani; Daniel Hayoz
Journal:  Hypertension       Date:  2004-08-09       Impact factor: 10.190

8.  Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis.

Authors:  Patrick H Dessein; Gavin R Norton; Angela J Woodiwiss; Barry I Joffe; Fred Wolfe
Journal:  J Rheumatol       Date:  2007-04-15       Impact factor: 4.666

9.  Production of angiotensin converting enzyme by rheumatoid synovial membrane.

Authors:  D Veale; G Yanni; B Bresnihan; O FitzGerald
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

10.  Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor.

Authors:  Sven Wassmann; Michaela Stumpf; Kerstin Strehlow; Andreas Schmid; Bernhard Schieffer; Michael Böhm; Georg Nickenig
Journal:  Circ Res       Date:  2003-12-29       Impact factor: 17.367

View more
  35 in total

1.  Role of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in airway reactivity and inflammation in an allergic mouse model of asthma.

Authors:  Mehaben Patel; Mangesh Kurade; Sahith Rajalingam; Riya Bhavsar; S Jamal Mustafa; Dovenia S Ponnoth
Journal:  Immunopharmacol Immunotoxicol       Date:  2019-05-07       Impact factor: 2.730

Review 2.  Angiotensin-converting enzyme in innate and adaptive immunity.

Authors:  Kenneth E Bernstein; Zakir Khan; Jorge F Giani; Duo-Yao Cao; Ellen A Bernstein; Xiao Z Shen
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

Review 3.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

4.  Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training.

Authors:  Mohammad Alturki; Keliane Liberman; Andreas Delaere; Liza De Dobbeleer; Veerle Knoop; Tony Mets; Siddhartha Lieten; Bert Bravenboer; Ingo Beyer; Ivan Bautmans
Journal:  Drugs Aging       Date:  2021-02-05       Impact factor: 3.923

5.  2K1C-activated Angiotensin II (Ang II) exacerbates vascular damage in a rat model of arthritis through the ATR/ERK1/2 signaling pathway.

Authors:  Ying Zhang; Xuexia Luo; Yue Zhou; Huaxun Wu; Jingyu Chen; Ying Wang; Danian Chen; Zhouwei Xu; Shangxue Yan; Wei Wei
Journal:  Inflamm Res       Date:  2017-06-26       Impact factor: 4.575

6.  Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats.

Authors:  Maha Mohammed Abdel-Fattah; Basim Anwar Shehata Messiha; Ahmed Mohamed Mansour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-17       Impact factor: 3.000

Review 7.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

8.  Chronic Treatment With the ACE Inhibitor Enalapril Attenuates the Development of Frailty and Differentially Modifies Pro- and Anti-inflammatory Cytokines in Aging Male and Female C57BL/6 Mice.

Authors:  Kaitlyn Keller; Alice Kane; Stefan Heinze-Milne; Scott A Grandy; Susan E Howlett
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-07-12       Impact factor: 6.053

Review 9.  Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.

Authors:  Federico Carbone; Aldo Bonaventura; Luca Liberale; Sabrina Paolino; Francesco Torre; Franco Dallegri; Fabrizio Montecucco; Maurizio Cutolo
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

10.  Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study.

Authors:  Dorien M C F Sluijsmans; Daphne C Rohrich; Calin D Popa; Bart J F van den Bemt
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.